RT Journal Article
SR Electronic
T1 Fine analysis of lymphocyte subpopulations in SARS-CoV-2 infected patients: toward a differential profiling of patients with severe outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.31.21262538
DO 10.1101/2021.08.31.21262538
A1 Clavarino, Giovanna
A1 Leroy, Corentin
A1 Epaulard, Olivier
A1 Raskovalova, Tatiana
A1 Vilotitch, Antoine
A1 Pernollet, Martine
A1 Dumestre-Pérard, Chantal
A1 Defendi, Federica
A1 Le Marechal, Marion
A1 Le Gouellec, Audrey
A1 Audoin, Pierre
A1 Bosson, Jean-Luc
A1 Poignard, Pascal
A1 Roustit, Matthieu
A1 Jacob, Marie-Christine
A1 Cesbron, Jean-Yves
YR 2021
UL http://medrxiv.org/content/early/2021/09/02/2021.08.31.21262538.abstract
AB COVID-19 is caused by the human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in widespread morbidity and mortality. CD4+ T cells, CD8+ T cells and neutralizing antibodies all contribute to control SARS-CoV-2 infection. However, heterogeneity is a major factor in disease severity and in immune innate and adaptive responses to SARS-CoV-2. We performed a deep analysis by flow cytometry of lymphocyte populations of 125 hospitalized SARS-CoV-2 infected patients on the day of hospital admission. Five clusters of patients were identified using hierarchical classification on the basis of their immunophenotypic profile, with different mortality outcomes. Some characteristics were observed in all the clusters of patients, such as lymphopenia and an elevated level of effector CD8+CCR7- T cells. However, low levels of T cell activation are associated to a better disease outcome; on the other hand, profound CD8+ T-cell lymphopenia, a high level of CD4+ and CD8+ T-cell activation and a high level of CD8+ T-cell senescence are associated with a higher mortality outcome. Furthermore, a cluster of patient was characterized by high B-cell responses with an extremely high level of plasmablasts. Our study points out the prognostic value of lymphocyte parameters such as T-cell activation and senescence and strengthen the interest in treating the patients early in course of the disease with targeted immunomodulatory therapies based on the type of adaptive response of each patient.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04596098Funding StatementNo external funding was received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the prospective study was given by the relevant ethics committee (Comite de Protection des Personnes Ile de France II, IDRCB: 2020-A00904-35) CPP Ile de France II 60 Boulevard du Marechal Martial Valin, CS 21623 75509 PARIS CEDEX 15 Bureau : President : Stephane DONNADIEU Vice-Presidente : Marie-France MAMZER-BRUNEEL Secretaires : Laura CHEVREAU, Pierre COLONNA Membres : C. ARDIOT, C. BALLOUARD, J.-L. BRESSON, C. BROISSAND, M. DE FALLOIS, A.GOUEL, L.GUEST, M-C LAI, M.LARGEAU, C. MARTINEAUX, M.SEHAN, L.VALENTINO, M. WACK, R.JACOB-VESTLING Secretariat : Nora VESTRISAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript